Published in Pediatr Blood Cancer on October 01, 2010
Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes. Diagn Pathol (2012) 0.88
Eosinophilic myeloproliferative disorders. Hematology Am Soc Hematol Educ Program (2011) 0.88
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) (2013) 0.83
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol (2012) 2.95
[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene]. Ugeskr Laeger (2006) 1.39
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur J Haematol (2007) 1.33
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res (2013) 1.10
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn (2011) 1.06
High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol (2012) 1.01
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology (2009) 0.98
Microarray-based classification of diffuse large B-cell lymphoma. Eur J Haematol (2005) 0.97
Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood (2011) 0.95
Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2007) 0.93
Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol (2014) 0.92
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology (2008) 0.91
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome? Oncotarget (2014) 0.87
Prognostic significance of metallothionein in B-cell lymphomas. Blood (2006) 0.86
Systemic mastocytosis--a systematic review. Dan Med J (2012) 0.84
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis. Eur J Haematol (2013) 0.82
Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. J Allergy Clin Immunol (2012) 0.81
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol (2013) 0.81
KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis. Dermatology (2013) 0.80
Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol (2007) 0.80
Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. APMIS (2007) 0.79
Validation of putative reference genes for normalization of Q-RT-PCR data from paraffin-embedded lymphoid tissue. Diagn Mol Pathol (2009) 0.79
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. Leuk Lymphoma (2012) 0.78
Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. Leuk Lymphoma (2015) 0.77
Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. APMIS (2007) 0.75
[New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation]. Ugeskr Laeger (2006) 0.75
[Improved survival in children with neuroblastoma]. Ugeskr Laeger (2010) 0.75
[New disease markers within the chronic myeloproliferative neoplasms]. Ugeskr Laeger (2015) 0.75
[Hip pain as a paraneoplastic rheumatic syndrome in a patient with double-hit lymphoma]. Ugeskr Laeger (2014) 0.75
[Mastocytosis]. Ugeskr Laeger (2016) 0.75
Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient. Pediatr Blood Cancer (2014) 0.75
Myeloid sarcoma developing in pre-existing pyoderma gangrenosum. Acta Derm Venereol (2009) 0.75
[Hemophagocytosis associated with cytomegalovirus infection and azathioprine treatment for inflammatory bowel disease]. Ugeskr Laeger (2010) 0.75